Alto De-Risks Precision Approach To Psychiatry With Phase IIa Depression Success
Phase IIb Trial Imminent
Executive Summary
The US biotech’s candidate, ALTO-100, has hit the mark in a Phase IIa depression trial, de-risking the firm’s novel precision approach to psychiatry R&D and triggering the start of a Phase IIb study.